TABLE III.

Genes and PD-L1 biomarker detected in the reference and adoption scenarios^a

Gene or biomarker	Detections (n)
	Adoption scenario
	Reference scenario (single-gene testing only)	1b			2c			3d			4e
		Conv.	FO	Total	Conv.	FO	Total	Conv.	FO	Total	Conv.	FO	Total
Reference scenario 1: Single-gene testing only
ALK	102	51	77	128	Not applicable			Not applicable			102	7	109
PD-L1	1466	1466	0	1466							1466	0	1466
EGFR	456	228	374	602							456	34	490
KRAS	45	22	598	620							45	54	99
BRAF	4	2	107	109							4	10	13
ROS1	21	11	27	37							21	2	24
ERBB2	0	0	112	112							0	10	10
MET	0	0	155	155							0	14	14
RET	0	0	45	45							0	4	4
Unmatched	3016	1834									2880
Reference scenario 2: Single-gene testing followed by hotspot panel
ALK	102	51	77	128	62	63	124	80	37	117	102	7	109
PD-L1	1466	1466	0	1466	1466	0	1466	1466	0	1466	1466	0	1466
EGFR	456	228	374	602	228	302	530	332	180	512	456	34	490
KRAS	671	335	598	933	335	484	819	488	288	776	671	54	725
BRAF	54	27	107	134	27	86	113	39	51	90	54	10	63
ROS1	21	11	27	37	21	22	43	14	13	27	21	2	24
ERBB2	0	0	112	112	0	91	91	0	54	54	0	10	10
MET	0	0	155	155	0	125	125	0	75	75	0	14	14
RET	0	0	45	45	0	37	37	0	22	22	0	4	4
Unmatched	2340	1497			1761			1970			2204

^aScenarios 1–3 assume 50% uptake for FoundationOne CDx (Foundation Medicine, Cambridge, MA, U.S.A.). PD-L1 expression is immunohistochemical assays and used in conjunction with FoundationOne testing.

^bFoundationOne CDx replaces all reflex testing.

^cFoundationOne CDx replaces hotspot panel.

^dFoundationOne CDx used after negative reflex and hotspot panel.

^eFoundationOne Liquid testing only.

Conv. = conventional testing; FO = FoundationOne testing.